Dyne Therapeutics (DYN) to Announce Earnings on Tuesday

Dyne Therapeutics (NASDAQ:DYN) is expected to be announcing its earnings results before the market opens on Tuesday, March 4th. Analysts expect the company to announce earnings of ($0.92) per share for the quarter.

Dyne Therapeutics Trading Down 3.0 %

DYN stock opened at $13.59 on Tuesday. The stock has a 50-day moving average price of $17.88 and a two-hundred day moving average price of $28.35. Dyne Therapeutics has a 12-month low of $13.07 and a 12-month high of $47.45. The company has a market cap of $1.38 billion, a PE ratio of -3.82 and a beta of 1.11.

Insider Buying and Selling

In related news, SVP Richard William Scalzo sold 1,455 shares of the business’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total value of $40,914.60. Following the transaction, the senior vice president now owns 127,078 shares in the company, valued at approximately $3,573,433.36. The trade was a 1.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Oxana Beskrovnaya sold 2,334 shares of the business’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total value of $65,632.08. Following the completion of the transaction, the insider now owns 201,685 shares in the company, valued at approximately $5,671,382.20. This trade represents a 1.14 % decrease in their position. The disclosure for this sale can be found here. Insiders own 20.77% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on DYN shares. Raymond James raised Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Baird R W raised Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Chardan Capital reissued a “buy” rating and set a $50.00 price target on shares of Dyne Therapeutics in a research report on Friday, January 10th. Guggenheim reissued a “buy” rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $45.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, January 14th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Dyne Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $49.91.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.